Comera Life Sciences Holdings, Inc.

As of August 10, 2023, Comera Life Sciences Holdings, Inc. is considered risky and overvalued, with a P/E ratio of -0.0007 and poor performance, returning -99.2% over the past year compared to the S&P 500's 10.26%.

As of June 12, 2025, the market trend is neutral with mixed signals; while the MACD and RSI indicate mild bullishness on longer time frames, daily moving averages suggest a bearish position, resulting in a lack of strong momentum.

As of Jun 16, Comera Life Sciences Holdings, Inc. has a market capitalization of 0.01, classifying it as a Micro Cap, with net sales of 1.01 million and a net profit loss of 9.03 million over the last four quarters. The company's shareholder's funds were -1.73 million, and total assets were 3.73 million as of Dec 22.